证券代码：000661 证券简称：长春高新 长春高新技术产业（集团）股份有限公司 投资者关系活动记录表 编号：2023-004 | --- | --- | --- | |----------------|------------------------------|----------------------------------------------------------| | | □特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | | 投资者关系活动 | | | | | □新闻发布会 | □路演活动 | | 类别 | | | | | □现场参观 | | | | √其他 电话会议 | | | | point 72 | 、安信基金、贝莱德、博时基金、大成基金、大家资 | | | | 管、德邦证券、东方红资管、东方证券、东吴基金、富国基金、 | | | | 工银瑞信基金、光大保德信、广发基金、国海富兰克林基金、 | | | | 国金证券、国泰基金、国投瑞银基金、宏利基金、华安证券、 | | | | 华宝基金、华商基金、海通证券、华泰柏瑞基金、华泰资管、 | | | | 华夏基金 ...

届时公司董事长马骥先生，董事、总经理姜云涛先生，副总经理、财务总 监朱兴功先生，董事会秘书张德申先生将通过网络在线问答互动的形式，与投 资者就经营业绩等投资者关注的问题进行交流。期间，前述人员将全程在线， 实时回答投资者的提问。投资者可于 2023 年 5 月 19 日（星期五）17：00 前访 问 http://ir.p5w.net/zj/，或扫描下方二维码，进入问题征集专题页面。欢 迎广大投资者积极参与。 证券代码：000661 证券简称：长春高新 公告编号：2023-046 长春高新技术产业（集团）股份有限公司 关于参加网上集体业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，长春高新技术产业（集团）股份有限 公司（以下简称"公司"）将参加由吉林证监局、吉林省证券业协会、深圳市全 景网络有限公司共同举办的"2023 年吉林辖区上市公司网上集体业绩说明 会"，现将有关事项公告如下： 本次集体业绩说明将通过深圳市全景网络有限公司提供的互联网平台举 行 ， 投 资 者 可 以 登 录 全 景 网 " 投 资 者 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 2.78 billion, a decrease of 6.63% compared to the same period last year[5]. - Net profit attributable to shareholders was CNY 856.99 million, down 24.71% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was CNY 854.01 million, a decline of 23.93% compared to the previous year[5]. - Basic earnings per share decreased to CNY 2.13, down 24.73% from CNY 2.83 in the same period last year[5]. - Net profit for the period was CNY 1,047,130,861.22, down 23.7% from CNY 1,372,310,481.87 in the same quarter last year[21]. - The net profit for Q1 2023 was ¥859,198,906.19, a decrease of 25% compared to ¥1,145,274,026.14 in Q1 2022[22]. - The total comprehensive income for Q1 2023 was ¥852,300,642.03, down from ¥1,133,849,287.35 in the same period last year[22]. Cash Flow and Liquidity - The net cash flow from operating activities increased by 55.21% to CNY 936.67 million[5]. - Cash and cash equivalents at the end of Q1 2023 were CNY 6,001,830,360.88, up 7.6% from CNY 5,578,512,789.74 at the beginning of the year[15]. - Operating cash flow for Q1 2023 was ¥936,665,805.67, an increase of 55% compared to ¥603,486,976.75 in Q1 2022[24]. - The company reported a net cash increase of ¥360,421,074.68 for the quarter, contrasting with a decrease of ¥284,724,036.90 in Q1 2022[25]. - The cash flow from financing activities showed a net outflow of -¥83,894,379.73, improving from -¥496,264,533.70 in the same quarter last year[25]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 26.77 billion, an increase of 2.87% from the end of the previous year[5]. - Total assets increased to CNY 26,774,571,937.99, compared to CNY 26,027,362,994.80 at the start of the year, reflecting a growth of 2.9%[18]. - Total liabilities decreased to CNY 5,080,624,430.21 from CNY 5,220,865,791.33, a reduction of 2.7%[18]. - The company’s total equity rose to CNY 21,693,947,507.78, an increase of 4.3% from CNY 20,806,497,203.47 at the beginning of the year[18]. Research and Development - R&D expenses increased by 42.81% year-on-year, amounting to CNY 3.34 billion, primarily due to increased investment in the pharmaceutical subsidiary[9]. - R&D expenses rose significantly to CNY 334,939,252.04, an increase of 42.7% compared to CNY 234,535,809.05 in the previous year[21]. Subsidiary Performance - The subsidiary Jinsai Pharmaceutical achieved revenue of CNY 2.35 billion and a net profit of CNY 895 million[9]. - The company reported a 36.38% decrease in accounts receivable notes, totaling CNY 0.88 billion, mainly due to increased payments from the pharmaceutical subsidiary[9].

证券代码：000661 证券简称：长春高新 公告编号：2023-031 长春高新技术产业（集团）股份有限公司 关于举办 2022 年度及 2023 年第一季度业绩说明会的公告 （投资者提问征集专题页面二维码） 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 长春高新技术产业（集团）股份有限公司（以下简称"公司"）已于 2023 年 3 月 30 日披露 2022 年年度报告，并拟于 2023 年 4 月 18 日披露 2023 年第一 季度报告。为便于广大投资者进一步了解公司 2022 年度及 2023 年第一季度生 产经营情况及未来发展规划，公司定于 2023 年 4 月 21 日（星期五）13:30- 17:00 举办 2022 年度及 2023 年第一季度业绩说明会。本次业绩说明会采用网 络视频直播的方式举行，欢迎广大投资者积极参与。 一、业绩说明会的安排 1、召开时间：2023 年 4 月 21 日 13:30-17:00 4、出席人员 董事长马骥先生，董事、总经理姜云涛先生，董事、常务副总经理叶朋先 生，独立董事李春好先生，副总经理李秀峰先生，副总经 ...

Financial Performance - The company's operating revenue for 2022 was CNY 12,627,188,966.71, representing a 17.50% increase compared to CNY 10,746,717,262.21 in 2021[19]. - The net profit attributable to shareholders of the listed company was CNY 4,140,114,115.74, an increase of 10.18% from CNY 3,757,472,953.11 in the previous year[19]. - The net profit after deducting non-recurring gains and losses was CNY 4,118,413,628.66, up 10.06% from CNY 3,742,099,607.18 in 2021[19]. - The basic earnings per share for 2022 was CNY 10.29, reflecting a 10.88% increase from CNY 9.28 in 2021[19]. - The total assets at the end of 2022 were CNY 26,027,362,994.80, a 15.60% increase from CNY 22,515,769,520.78 at the end of 2021[19]. - The net assets attributable to shareholders of the listed company increased by 23.85% to CNY 18,049,805,753.49 from CNY 14,573,728,469.70 in the previous year[19]. - The net cash flow from operating activities decreased by 15.14% to CNY 2,826,408,333.06 from CNY 3,330,619,225.29 in 2021[19]. - The weighted average return on equity was 25.71%, down from 28.81% in the previous year, indicating a decrease of 3.10%[19]. Revenue and Profit Breakdown - In 2022, the company's total revenue for the four quarters was approximately CNY 12.63 billion, with the highest revenue in Q3 at CNY 3.81 billion[23]. - The net profit attributable to shareholders for the year was approximately CNY 4.14 billion, with Q1 showing the highest profit of CNY 1.14 billion[23]. - The net cash flow from operating activities for the year totaled approximately CNY 2.83 billion, with Q4 contributing the most at CNY 1.23 billion[23]. - The pharmaceutical sector contributed ¥11,948,609,181.07, accounting for 94.63% of total revenue, with a growth of 18.93% from ¥10,046,374,067.81 in 2021[60]. - Gene engineering and biological drugs generated ¥11,290,164,405.57, which is 89.42% of total revenue, showing a 20.05% increase from ¥9,404,719,539.29 in the previous year[60]. Research and Development - R&D investment reached 1.663 billion yuan, showing a significant increase of 52.26% year-on-year[48]. - The proportion of R&D investment to operating revenue increased by 3.01% to 13.17% in 2022[77]. - R&D personnel increased by 17.30% to 1,146 in 2022, with the proportion of R&D staff rising to 12.96% of total employees[76]. - The company is investing heavily in R&D, with an allocation of 200 million yuan for the development of new biopharmaceuticals and vaccines in the upcoming year[34]. - The company is conducting Phase III clinical trials for recombinant human growth hormone injection for chronic kidney disease-related growth disorders[73]. - The company is also in Phase II clinical trials for polyethylene glycol recombinant human growth hormone injection for various growth disorders[73]. Market Expansion and Product Development - The company has set a revenue guidance for the next fiscal year, projecting a growth rate of 25% to 30%[34]. - New product launches include a series of innovative vaccines, such as the varicella live attenuated vaccine and the inactivated rabies vaccine, aimed at enhancing the company's market position in the vaccine sector[34]. - The company is actively expanding its product lines in assisted reproduction and women's health, aiming for dual growth in its main business areas[40]. - The company is focusing on optimizing its product innovation and enhancing operational performance through a robust marketing team of approximately 4,100 personnel[46]. - The company is exploring potential acquisitions to strengthen its portfolio, with a budget of 500 million yuan allocated for this purpose in 2023[121]. Corporate Governance and Management - The company has a governance structure that ensures independence from its controlling shareholder, maintaining a complete business system and financial independence[106]. - The board of directors consists of 9 members, including 3 independent directors, ensuring effective governance and decision-making[106]. - The company has established a multi-level incentive system to attract and retain quality talent, focusing on internal promotion and external recruitment[100]. - The company has implemented a strict insider information management system to prevent leaks during the preparation of periodic reports and major events[108]. - The company has conducted multiple investor communications, including a conference call with 231 institutional investors to discuss operational performance[103]. Environmental and Social Responsibility - The company is classified as a key pollutant discharge unit by environmental protection authorities, adhering to multiple environmental protection laws and standards[156]. - The company has publicly disclosed its environmental, social, and governance (ESG) report for 2022, detailing its social responsibility efforts[173]. - The company has made significant investments in environmental protection initiatives as part of its corporate social responsibility strategy[171]. - The company has undergone environmental impact assessments for its construction projects, ensuring compliance with environmental regulations[158]. - The company has established effective waste gas treatment systems in its workshops and R&D facilities[168]. Future Outlook - The company provided a positive outlook for 2023, projecting a revenue growth of 25% and aiming to reach 1.875 billion yuan[117]. - The company plans to enhance operational efficiency, targeting a reduction in costs by 15% through process optimization initiatives[123]. - The company is focused on maintaining its independence and operational capabilities, ensuring no conflicts with controlling shareholders[109]. - The company is committed to enhancing its core competitiveness through product structure improvement, sales model optimization, and new business development[98].